GTS-21

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H20N2O2
Molecular Weight	308.3743
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(\C=C2/CCCN=C2C3=CC=CN=C3)C(OC)=C1

InChI

InChIKey=RPYWXZCFYPVCNQ-RVDMUPIBSA-N

InChI=1S/C19H20N2O2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16/h3,6-9,11-13H,4-5,10H2,1-2H3/b15-11+

HIDE SMILES / InChI

Molecular Formula	C19H20N2O2
Molecular Weight	308.3743
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00419445 | https://clinicaltrials.gov/ct2/show/NCT01400477 | https://adisinsight.springer.com/drugs/800005633 | https://clinicaltrials.gov/ct2/show/NCT02432066

GTS-21 (also known as DMBX-A), a selective alpha-7 nicotinic acetylcholine receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. GTS-21 has been studied in Phase II in patients with schizophrenia and in patients with Alzheimer disease. However, these studies were discontinued. GTS-21 was also involved in phase II to reduce negative affect, improve cognition and/or reduce smoking relapse in healthy adult men and women who are chronic cigarette smokers. However, this study was withdrawn. Besides, GTS-21 has participated in phase II to investigate safety and efficacy in adults with attention-deficit hyperactivity disorder.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Neuronal acetylcholine receptor subunit alpha-7 14 Target ID: P36544 Gene ID: 1139\|\|\|89832 Gene Symbol: CHRNA7 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15213292	Agonist 2678		11.0 µM [EC50]

PubMed

Title	Date	PubMed
Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant.	1999 Feb 5	10082212
Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease.	1999 Jul	10456692
Selective alpha 7 nicotinic receptor stimulation normalizes chronic cocaine-induced loss of hippocampal sensory inhibition in C3H mice.	1999 Nov 15	10578459
GTS-21, a mixed nicotinic receptor agonist/antagonist, does not affect the nicotine cue.	1999 Oct	10515327
The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).	2000 Aug	10942043
Genetic and pharmacological strategies identify a behavioral function of neuronal nicotinic receptors.	2000 Aug	10942032
Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers.	2003 Mar	12629535
GABAergic systems modulate nicotinic receptor-mediated seizures in mice.	2003 Sep	12829730
Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.	2004 Jun	15205879

Sample Use Guides

In Vivo Use Guide

GTS21 25/75/150 mg tid

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:07:00 GMT 2023` Edited by `admin` on `Fri Dec 15 16:07:00 GMT 2023`
Record UNII	8S399XDN2K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GTS-21

Common Name

English

3-2,4 DIMETHOXBENZYLIDENE ANABASEINE

Common Name

English

3-(2,4-DIMETHOXYBENZYLIDENE)ANABASEINE

Common Name

English

DMXB-A

Common Name

English

DIMETHOXYBENZYLIDENE ANABASEINE

Common Name

English

Code System Code Type Description

CLINICAL_TRIALS.GOV

NCT00952393